Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, has won the Star of Innovation award at the 9th annual European Small and Mid-Cap Awards. The award win recognises Nanoform as a listed company that places innovation at the centre of its strategy for business development and introduces an innovative technology to the market. On the same night, November 16th 2021, Nanoform was also shortlisted for two further awards at the European Mediscience Awards, which took place in London. This was a great accolade as many of the award winners were rightly recognised for their outstanding contributions to COVID, such as AstraZeneca and BioNTech. To be in the presence of industry drug development giants shows that small continues to be powerful.
The European Small and Mid-Cap Awards, launched in 2013, were established by the European Commission to recognise selected European listed growth companies. EuropeanIssuers, who represent listed companies, and the Federation of European Securities Exchanges (FESE), who represent European stock exchanges, are co-organisers of the event.
Nanoform, listed on Nasdaq, was shortlisted out of 27 nominations from 17 countries, listed on different European stock exchanges.
Prof Edward Hæggström, Nanoform CEO, commented: “We are honored to have received the Star of Innovation award within European Small and Mid-Cap Awards 2021. Patients’ lives depend on innovation, and they are at the heart of all that we do in Nanoform. We would like to thank the European Commission, EuropeanIssuers and the Federation of European Securities Exchanges for recognising our innovation, Nasdaq IPO, job creation and speed of growth. European capital markets are highly efficient, and we are grateful for the endorsement. In future, we look forward to continue being an important part of the European growth engine.”
